XML 12 R46.htm IDEA: XBRL DOCUMENT v2.4.0.6
Business Segment Information (Details) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 6 Months Ended
Oct. 31, 2012
Oct. 31, 2011
Oct. 31, 2012
Oct. 31, 2011
Net revenue $ 1,458 $ 1,741 $ 3,564 $ 3,372
Sales and marketing costs 680 651 1,389 1,262
Stock- based compensation expense 624 855 1,364 1,868
Personalized Oncology Solutions [Member]
        
Net revenue 459 590 1,377 1,188
Direct cost of services (576) (461) (1,293) (945)
Sales and marketing costs (378) (369) (814) (676)
Other operating expenses 0 0 0 0
Stock- based compensation expense 0 [1] 0 [1] 0 [1] 0 [1]
Segment profit (loss) (495) (240) (730) (433)
Translational Oncology Solutions [Member]
        
Net revenue 999 1,151 2,187 2,184
Direct cost of services (471) (604) (1,162) (1,072)
Sales and marketing costs (241) (221) (432) (466)
Other operating expenses (433) (984) (794) (1,568)
Stock- based compensation expense 0 [1] 0 [1] 0 [1] 0 [1]
Segment profit (loss) (146) (658) (201) (922)
Unallocated Corporate Overhead [Member]
        
Net revenue 0 0   0
Direct cost of services 0 0   0
Sales and marketing costs 0 0   0
Other operating expenses (651) (716) (1,221) (1,462)
Stock- based compensation expense (624) [1] (855) [1] (1,364) [1] (1,868) [1]
Segment profit (loss) (1,275) (1,571) (2,585) (3,330)
Consolidated [Member]
        
Net revenue 1,458 1,741 3,564 3,372
Direct cost of services (1,047) (1,065) (2,455) (2,017)
Sales and marketing costs (619) (590) (1,246) (1,142)
Other operating expenses (1,084) (1,700) (2,015) (3,030)
Stock- based compensation expense (624) [1] (855) [1] (1,364) [1] (1,868) [1]
Segment profit (loss) $ (1,916) $ (2,469) $ (3,516) $ (4,685)
[1] Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.